Teriparatide (recombinant human parathyroid hormone 1-34) in postmenopausal women with osteoporosis: systematic review.

CONTEXT AND OBJECTIVE Osteoporosis is defined as a disease characterized by low bone mass and deterioration of the bone tissue microarchitecture. Teriparatide stimulates the formation and action of osteoblasts, which are responsible for bone formation, thus promoting bone tissue increase. The aim was to assess the effectiveness and safety of teriparatide for treating postmenopausal osteoporosis. METHODS A systematic review was conducted using the Cochrane Collaboration methodology. RESULTS 1) Teriparatide 20 microg or 40 microg versus placebo: there was a benefit from teriparatide, considering the following outcomes: reduction in the number of new vertebral and non-vertebral fractures, and increased whole-body, lumbar and femoral bone mineral density. 2) Teriparatide 40 microg versus alendronate 10 mg/day for 14 months: there was no statistical difference regarding the incidence of new vertebral or non-vertebral fractures, although in the group that received teriparatide there was greater bone mineral density increase in the whole body, lumbar column and femur. 3) Estrogen plus teriparatide 25 microg versus estrogen: there was a benefit, considering the following outcomes: reduction in the number of new vertebral fractures, and increased whole-body, lumbar and femoral bone mineral density after three years. CONCLUSIONS When teriparatide is intermittently administered in low doses, it reduces the incidence of vertebral fractures (67%) and non-vertebral fractures (38%) and increases bone mineral density in the lumbar column and femur. There is a need for studies with longer observation in order to allow conclusions regarding the safety and duration of the therapeutic effects.

[1]  Michele Tarsilla.  Cochrane Handbook for Systematic Reviews of Interventions , 2010, Journal of MultiDisciplinary Evaluation.

[2]  J. Kaufman,et al.  Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: treatment and discontinuation of therapy , 2005, Osteoporosis International.

[3]  N. Lane,et al.  Changes in serum receptor activator of nuclear factor-kappaB ligand, osteoprotegerin, and interleukin-6 levels in patients with glucocorticoid-induced osteoporosis treated with human parathyroid hormone (1-34). , 2004, The Journal of clinical endocrinology and metabolism.

[4]  R. Lindsay,et al.  Efficacy and safety of human parathyroid hormone-(1-84) in increasing bone mineral density in postmenopausal osteoporosis. , 2004, The Journal of clinical endocrinology and metabolism.

[5]  R. Lindsay,et al.  Efficacy and Safety of Human Parathyroid Hormone-(1–84) in Increasing Bone Mineral Density in Postmenopausal Osteoporosis , 2003 .

[6]  H. Genant,et al.  Recombinant Human Parathyroid Hormone (1–34) [Teriparatide] Improves Both Cortical and Cancellous Bone Structure , 2003, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[7]  Mary L Bouxsein,et al.  The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. , 2003, The New England journal of medicine.

[8]  Laura B. Hansen,et al.  Current approaches to the prevention and treatment of postmenopausal osteoporosis. , 2003, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[9]  A. Díez-Pérez,et al.  The Effect of Teriparatide [Human Parathyroid Hormone (1–34)] Therapy on Bone Density in Men With Osteoporosis , 2003, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[10]  R. Marcus,et al.  The Skeletal Response to Teriparatide Is Largely Independent of Age, Initial Bone Mineral Density, and Prevalent Vertebral Fractures in Postmenopausal Women With Osteoporosis , 2003, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[11]  ALX 111: ALX1-11, parathyroid hormone (1-84) - NPS Allelix, PREOS, PTH, recombinant human parathyroid hormone, rhPTH (1-84). , 2003, Drugs in R&D.

[12]  N. Lane,et al.  Daily treatment with parathyroid hormone is associated with an increase in vertebral cross-sectional area in postmenopausal women with glucocorticoid-induced osteoporosis , 2003, Osteoporosis International.

[13]  H. Rodbard,et al.  American Association of Clinical Endocrinologists medical guidelines for clinical practice for the prevention and treatment of postmenopausal osteoporosis: 2001 edition, with selected updates for 2003. , 2003, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[14]  P. Kulkarni,et al.  A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1-34)] with alendronate in postmenopausal women with osteoporosis. , 2002, The Journal of clinical endocrinology and metabolism.

[15]  P. Delmas,et al.  Treatment of postmenopausal osteoporosis , 2002, The Lancet.

[16]  J. Kanis,et al.  Diagnosis of osteoporosis and assessment of fracture risk , 2002, The Lancet.

[17]  Jacques P. Brown,et al.  2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. , 2002, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[18]  S. Gabriel,et al.  Impact of Hip and Vertebral Fractures on Quality-Adjusted Life Years , 2001, Osteoporosis International.

[19]  J. Reginster,et al.  Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. , 2001, The New England journal of medicine.

[20]  P Geusens,et al.  Risk of new vertebral fracture in the year following a fracture. , 2001, JAMA.

[21]  D. Doherty,et al.  Lifetime and Five-Year Age-Specific Risks of First and Subsequent Osteoporotic Fractures in Postmenopausal Women , 2001, Osteoporosis International.

[22]  R. Lindsay,et al.  Parathyroid hormone as a therapy for idiopathic osteoporosis in men: effects on bone mineral density and bone markers. , 2000, The Journal of clinical endocrinology and metabolism.

[23]  J. Adachi,et al.  Histomorphometric evidence for increased bone turnover without change in cortical thickness or porosity after 2 years of cyclical hPTH(1-34) therapy in women with severe osteoporosis. , 2000, Bone.

[24]  H. Genant,et al.  Bone Mass Continues to Increase at the Hip After Parathyroid Hormone Treatment Is Discontinued in Glucocorticoid‐Induced Osteoporosis: Results of a Randomized Controlled Clinical Trial , 2000, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[25]  G. Willick,et al.  The Bone-Building Action of the Parathyroid Hormone , 1999, Drugs & aging.

[26]  H. Genant,et al.  Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. Results of a randomized controlled clinical trial. , 1998, The Journal of clinical investigation.

[27]  R. Lindsay,et al.  Parathyroid responsivity in postmenopausal women with osteoporosis during treatment with parathyroid hormone. , 1998, The Journal of clinical endocrinology and metabolism.

[28]  R. Lindsay,et al.  Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis , 1997, The Lancet.

[29]  L. Stitt,et al.  A randomized controlled trial to compare the efficacy of cyclical parathyroid hormone versus cyclical parathyroid hormone and sequential calcitonin to improve bone mass in postmenopausal women with osteoporosis. , 1997, The Journal of clinical endocrinology and metabolism.

[30]  A R Jadad,et al.  Assessing the quality of reports of randomized clinical trials: is blinding necessary? , 1996, Controlled clinical trials.

[31]  E. Barrett-Connor,et al.  Late Physical and Functional Effects of Osteoporotic Fracture in Women: The Rancho Bernardo Study , 1995, Journal of the American Geriatrics Society.

[32]  J. Kanis,et al.  DIAGNOSIS OF OSTEOPOROSIS , 2016 .

[33]  A. Klibanski,et al.  Parathyroid hormone for the prevention of bone loss induced by estrogen deficiency. , 1994, The New England journal of medicine.

[34]  C. Cooper,et al.  Perspective how many women have osteoporosis? , 1992, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[35]  Claus Christiansen,et al.  Diagnosis of Osteoporosis , 1992, Southern medical journal.

[36]  Consensus development conference: prophylaxis and treatment of osteoporosis. , 1991, Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA.

[37]  A. Hodsman,et al.  Biochemical responses to sequential human parathyroid hormone (1-38) and calcitonin in osteoporotic patients. , 1990, Bone and mineral.